Tests a new drug added to chemotherapy for advanced bowel cancer
Tests INCA33890 with chemotherapy and bevacizumab in adults with advanced colorectal cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Key facts
- Where
- Badalona, Barcelona, Las Palmas de Gran Canaria, Madrid, Majadahonda, Palma, Pamplona, Santander, Terrassa, Valencia, and Zaragoza, SpainSee the 15 sites
- Phase
- Phase 3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- How many different drug treatment plans (such as chemotherapy) have you had for cancer that has spread?
- Has a test of your tumour shown a change (mutation) in the KRAS, NRAS or BRAF genes?
- Has a test shown that your tumour is 'MSI-high' or 'dMMR'?
- Which best describes how well you can look after yourself and be active?
Source: NCT07284849, who can take part
Where in Spain
- Hospital Germans Trias i PujolBadalona, SpainNot yet recruiting
- Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
- Hospital Santa Creu i Sant PauBarcelona, SpainNot yet recruiting
- Hospital Universitari Vall d'HebronBarcelona, SpainNot yet recruiting
- Complejo Hospitalario Universitario Insular Materno InfantilLas Palmas de Gran Canaria, SpainNot yet recruiting
- Hospital General Universitario Gregorio MarañónMadrid, SpainNot yet recruiting
- Hospital Universitario 12 de OctubreMadrid, SpainNot yet recruiting
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainNot yet recruiting
- Hospital Universitario Puerta de Hierro de MajadahondaMajadahonda, SpainNot yet recruiting
- University Hospital Son EspasesPalma, SpainNot yet recruiting
- Hospital Universitario de NavarraPamplona, SpainNot yet recruiting
- Hospital Universitario Marqués de ValdecillaSantander, SpainNot yet recruiting
- Hospital Universitari Mutua TerrassaTerrassa, SpainNot yet recruiting
- Hospital Clinico Universitario de ValenciaValencia, SpainNot yet recruiting
- Hospital Universitario Miguel ServetZaragoza, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT07284849EU 2025-523735-19-00
- Record updated
- 30 October 2026
- Original description
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.Read full original descriptionShow less
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
Inclusion: Stage IV colorectal adenocarcinoma not amenable to curative resection; No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment; Measurable disease per RECIST v1.1; ECOG performance status of 0 or 1; Adequate organ function determined by laboratory results.
Exclusion: Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years; Significant concurrent and/or uncontrolled medical condition; History of other malignancy within 2 years; Active autoimmune disease that has required systemic treatment in the past 2 years; History of organ transplant, including allogeneic stem cell transplantation; Other protocol-defined inclusion/exclusion criteria apply; MSI-H/dMMR per historical data in the medical record; BRAF V600E mutation per historical data in the medical record; Untreated and/or progressing CNS metastases.